How Is ResMed’s Stock Performance Compared to Other Healthcare Stocks?

ResMed Inc. (RMD), headquartered in San Diego, California, is a leading developer, manufacturer, distributor, and marketer of medical devices and cloud-based software applications designed to diagnose, treat, and manage respiratory disorders both in the United States and internationally. With a market capitalization of $39.6 billion, ResMed operates through two main segments: Sleep and Breathing Health and Residential Care Software.

Large-cap stocks are typically defined as companies with a market capitalization of $10 billion or more, and ResMed falls into this category. Its substantial size, influence, and dominance in the medical instruments & supplies industry are evident through its market cap exceeding the $10 billion threshold.

ResMed reached a three-year high of $293.81 on August 22 and is currently trading 8.1% below that peak. Despite this slight dip, the stock has seen a 7.1% increase over the past three months, outperforming the Health Care Select Sector SPDR Fund’s marginal uptick during the same period.

The company’s long-term performance has also been impressive, with stock prices surging 18.1% in 2025 and 7.8% over the past 52 weeks. This outpaces the Health Care Select Sector SPDR Fund’s performance, which saw a marginal increase year-to-date and a decline over the past year.

ResMed’s stock has consistently traded above its 200-day and 50-day moving averages since late April, indicating a bullish trend with some minor fluctuations. This stability in trading patterns reflects investor confidence in the company’s prospects.

Following the release of its strong Q4 results on July 31, ResMed’s stock prices rose by 2.7%. The company ended fiscal 2025 on a high note, showcasing solid momentum across its business. Demand for its sleep and breathing health devices, as well as its digital health services, has remained robust. In Q4, ResMed’s net revenues grew by 10.2% year-over-year to $1.35 billion, surpassing Street expectations. Additionally, its non-GAAP EPS increased by 22.6% year-over-year to $2.55, exceeding consensus estimates.

Compared to its peer, Becton, Dickinson and Company (BDX), ResMed has significantly outperformed, with BDX experiencing a decline in both 2025 and over the past 52 weeks.

Analysts covering ResMed have given the stock a consensus “Moderate Buy” rating, with a mean price target of $289.25, suggesting a 7.1% upside potential from current levels.

In conclusion, ResMed’s strong performance, growth trajectory, and positive outlook make it a compelling investment opportunity in the medical devices sector. Investors looking for exposure to a leading player in respiratory disorder management may find ResMed to be a promising choice.